Lung Cancer TALK: A Review of Data from the IASLC 2020 World Conference on Lung Cancer - Episode 4

WCLC Updates in Neoadjuvant Therapy for NSCLC

March 5, 2021
Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center

,
Sarah Goldberg, MD, MPH, Yale School of Medicine

,
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

,
Heather A. Wakelee, MD, Stanford University Medical Center

Experts in thoracic oncology discuss the role of single-agent immunotherapy as neoadjuvant therapy and comment on the viability of MPR [major pathologic response] as a surrogate endpoint for non–small cell lung cancer (NSCLC).

Data from the following clinical trial are discussed: 

  •  PS01.05 - Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
x